Tagged with Switzerland

Switzerland Europe and Canada (EUCAN) have an essential role in Takeda’s global mission to advance healthcare innovation. Ricardo Marek, President of Takeda’s EUCAN division, discusses the operational and regulatory challenges, the importance of Switzerland as a strategic base, and Takeda’s post-Shire acquisition growth strategy.   Europe is central not just as…

Switzerland Fabrice Véricel and Geoffrey Folie explore UCB’s strategic growth, highlighting its European sites in Braine-l’Alleud, Belgium and Bulle, Switzerland and their roles in global pharmaceutical production. Key topics include the transition to biologics, embracing AI for process optimization, and sustainability initiatives.   Biomanufacturing thrives on complexity and collaboration, offering intellectual…

Switzerland Jérôme Garcin, newly appointed General Manager of Bristol-Myers Squibb (BMS) Switzerland, shares his journey to the role and discusses the strategic importance of the Swiss affiliate within the global BMS network. In this interview, he highlights BMS’s focus on innovation across therapeutic areas such as oncology, hematology, cardiology and neurology,…

Switzerland Giuseppe Grossi, General Manager of Daiichi Sankyo Switzerland, delves into the company’s strategic growth in cardiovascular and oncology, its commitment to innovation, and its dedication to making a meaningful impact in the Swiss healthcare landscape. Grossi highlights the importance of talent development, adaptability, and a focus on both local and…

Switzerland Anne Mette Wiis Vogelsang, CVP & General Manager of Novo Nordisk Switzerland, discusses Switzerland’s progressive healthcare landscape while addressing key issues like diabetes care, obesity, and systemic healthcare challenges. Vogelsang also calls for increased prioritization of a holistic approach to health, highlighting the importance of primary and secondary prevention, early…

Switzerland Bachem’s Thomas Meier highlights the company’s pivotal role as a CDMO in the rapidly evolving peptide and oligonucleotide markets, emphasizing strategic expansions, innovative manufacturing techniques, and a deep commitment to sustainability. With a vision for growth that includes both profitability and operational excellence, Bachem is poised to lead in therapeutic…

Switzerland Hendrik von Waldburg, Country Manager of Angelini Pharma S.p.A., Rom, Zweigniederlassung Zug, shares insights into the company’s ambitious vision for brain health and its expanding presence in the Swiss market. With a strong background in CNS and a focus on innovative therapies, Hendrik discusses the challenges and opportunities of building…

Switzerland Dennis Engelke, General Manager for Switzerland and Austria at Jazz Pharmaceuticals, discusses his career trajectory and the company’s growth in these markets. He highlights Jazz’s commitment to patient access and innovation, especially following the 2021 acquisition of GW Pharmaceuticals, which has enabled the company to enter the epilepsy space. Engelke…

Switzerland Michael Kubischik shares his career journey and Sanofi’s strategic focus in Switzerland. He highlights Sanofi’s dedication to become the world´s leading immunology company, supported by initiatives like AI integration and efficient regulatory processes to improve patient access, as well as the benefits of working for a company with such a…

Switzerland Georg Pirmin Meyer, SVP and Head of International at Blueprint Medicines, shares insights into the company’s journey from a promising startup to a fast-scaling biotech leader focused on allergy/inflammation and haematology/oncology. Meyer discusses Blueprint’s innovative approach to international expansion, patient-centric strategy, and ambitious plans for growth in new markets. He…

Switzerland Patrick Leimgruber of UPSA discusses the company’s strategic growth roadmap and ambitions to expand its product portfolio and reach EUR 1 billion in net sales by 2027. He also outlines the importance of Switzerland as one of the French company’s key markets, the challenges and opportunities presented by the Swiss…

Switzerland Founded in 2020 with a focus on diseases related to skeletal muscle damage, MUVON Therapeutics is currently targeting a significant unmet need in women’s health, Female Stress Urinary Incontinence (SUI). CEO & co-founder Deana Mohr-Haralampieva, outlines MUVON’s progress into phase II clinical trials and its plans to raise EUR 65…